Read about the AD/PDTM 2017 Conference which took place in Vienna, Austria on 29 March-2 April 2017.
"More than 3400 scientists from around the world attended the conference, which provided a platform to share the latest research, developments, and medical breakthroughs on Alzheimer's, Parkinson's, and other neurodegenerative diseases."
ALZFORUM Conference Coverage Series
International Conference on Alzheimer's & Parkinson’s Diseases 2017
"The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention."
"This five day conference saw over 3000 clinicians, researchers industry specialists from around the globe discuss recent advances in the field, including reports on the latest drug trails, new avenues for treatment and patient perspectives."
"There was clearly an expanse of common ground between them in terms of the research techniques being developed and the molecular pathways and cellular mechanisms being explored. It was encouraging to see researchers working on one condition learning from the successes and failures of those working in a related disease area."
"ProMIS Neurosciences, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announces results of its recent therapeutic developments presented at the 13th International Conference on Alzheimer's (AD) and Parkinson's diseases held in Vienna, Austria, from March 29 to April 2nd. This year's conference was devoted to mechanisms, clinical strategies and promising treatments of neurodegenerative diseases."
"Long-term use of the diabetes medication metformin may increase the risk for neurodegenerative disease in patients with type 2 diabetes mellitus (T2DM), new research suggests. The results were presented here at AD/PD 2017: The 13th International Conference on Alzheimer's and Parkinson's Diseases by Yi-Chun Kuan, MD, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan."
"Education, as a proxy for cognitive reserve, appears neuroprotective during early stages of the aging process but becomes less beneficial in later stages — and can even have a negative effect in patients with late amnestic mild cognitive impairment (aMCI) or mild Alzheimer's dementia (AD), new research suggests.However, those with late aMCI or mild AD had negative correlations in several brain areas, "showing a more disrupted resting-state functional network," lead author, Yeshin Kim, MD, Samsung Medical Center, Seoul, Republic of Korea, told attendees here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."
"Although past studies have shown that social relationships are important during the aging process, new research suggests that cognitive benefits may differ between types of social roles — at least in older women. Burn presented the findings here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."
"Decreased near-vision function in older patients may increase the risk for later dementia, new research suggests. "The main message is that clinicians need to be careful of eye vision and realize its importance for these patients," lead author, Virginie Nael. She presented the findings here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."
"Patients with enlarged brain ventricles and clinically suspected idiopathic normal-pressure hydrocephalus (iNPH) may be at increased risk for dementia, new research suggests... She presented the findings at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."
"Levels of iron in specific areas of the brain may help clinicians to differentiate a diagnosis of Parkinson's disease (PD) from nondegenerative tremor syndromes (ND-TS), suggests new imaging research. Still, lead author Sebastian Franthal, MD, Department of Neurology, Medical University of Graz, Austria, told attendees here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017 that the overall difference in brain-iron "is a novel finding."
"Throughout the Alzheimer's and Parkinson's Disease (AD/PD) Congress 2017, there were a number of recurring topics providing insight into the current and future focus of Alzheimer's disease (AD) research and development (R&D) efforts."
"During a forum discussion session at the Alzheimer's & Parkinson's Disease (AD/PD) Congress 2017, the panel of corporate executives from the leading players in Alzheimer's disease (AD) research, including Eli Lilly, Roche, Janssen, Eisai, and Biogen, discussed the lessons learned from the past failures and strategies for achieving success in the late stages of AD drug development. In response to some difficult questions from the audience, the panel highlighted targeting the wrong patient population, lack of biomarkers, and insufficient understanding of drugs’ mechanisms of action as some of the key contributors to the recent failures. They emphasized that companies must have clear strategies from early trial phases to tackle these challenges and to succeed in AD drug development."